📋 Disclosure: This post contains affiliate links. We may earn a commission if you sign up through our links — at no extra cost to you. Full disclosure.
🩺 Medical note: This content is for informational purposes only. Always consult your doctor before starting any medication. Full disclaimer.
Ozempic, Wegovy, and Mounjaro are the three most prescribed GLP-1 medications in the United States in 2026 — but they are not the same drug, they are not approved for the same conditions, and they do not produce the same results. Choosing between them without understanding the differences can mean paying more than necessary, using a drug not approved for your condition, or missing out on significantly better weight loss outcomes.
This guide compares all three drugs across every dimension that matters — active ingredient, FDA approval, cost, weight loss results, side effects, and availability — so you can have an informed conversation with your doctor about which option suits your situation.
Quick answer: Wegovy produces the most weight loss of any semaglutide drug (15% average body weight). Mounjaro (tirzepatide) produces even more (21% average). Ozempic is approved for type 2 diabetes, not weight loss — but is widely prescribed off-label. Mounjaro wins on results; Wegovy wins on insurance coverage for obesity; Ozempic wins on familiarity and availability.
The Basics — What Each Drug Is
Before comparing them, it helps to understand the landscape clearly.
Ozempic is a weekly injectable semaglutide medication manufactured by Novo Nordisk. It was FDA-approved in 2017 for the treatment of type 2 diabetes and cardiovascular risk reduction. It is not FDA-approved for weight loss — but is widely prescribed off-label for obesity because the weight loss effects are clinically significant.
Wegovy is also a weekly injectable semaglutide medication manufactured by Novo Nordisk. It contains the same active ingredient as Ozempic — semaglutide — but at a higher maximum dose (2.4mg vs 2mg for Ozempic). It was FDA-approved in 2021 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
Mounjaro is a weekly injectable tirzepatide medication manufactured by Eli Lilly. It was FDA-approved in 2022 for type 2 diabetes. Unlike Ozempic and Wegovy which activate only the GLP-1 receptor, Mounjaro activates two receptors — GLP-1 and GIP — producing stronger metabolic effects and greater weight loss.
The simplest way to remember the landscape:
Drug Company Approved for Active ingredient Ozempic Novo Nordisk Type 2 diabetes Semaglutide Wegovy Novo Nordisk Weight loss (obesity) Semaglutide Mounjaro Eli Lilly Type 2 diabetes Tirzepatide Zepbound Eli Lilly Weight loss (obesity) Tirzepatide
Active Ingredients — Semaglutide vs Tirzepatide
Semaglutide (Ozempic and Wegovy)
Semaglutide is a GLP-1 receptor agonist — a synthetic version of the naturally occurring GLP-1 hormone your body produces after eating. It works by:
- Stimulating insulin release in response to food (lowers blood sugar)
- Suppressing glucagon (reduces liver glucose output)
- Slowing gastric emptying (food stays in stomach longer — creates fullness)
- Acting on brain appetite centres to reduce hunger and food cravings
The result is significantly reduced appetite, lower caloric intake, and — over time — meaningful weight loss.
Tirzepatide (Mounjaro and Zepbound)
Tirzepatide is a dual GLP-1 and GIP receptor agonist — it activates two separate metabolic pathways simultaneously. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that enhances insulin sensitivity and fat metabolism differently to GLP-1.
The dual mechanism produces:
- Stronger appetite suppression than GLP-1 alone
- Better insulin sensitivity improvement
- Greater fat-specific weight loss with better muscle preservation
- Significantly higher total weight loss compared to semaglutide
The key difference: Tirzepatide’s dual mechanism produces approximately 6 percentage points more body weight reduction than semaglutide at maximum doses in head-to-head clinical comparison. This is a clinically significant difference.
FDA Approvals — What Each Drug Is Officially For
Understanding FDA approval status matters for insurance coverage, legal prescribing, and safety data.
Drug FDA approved for Year approved Off-label use Ozempic Type 2 diabetes, cardiovascular risk reduction 2017 Widely used for weight loss Wegovy Chronic weight management (obesity, overweight + comorbidity) 2021 Minimal — used as approved Mounjaro Type 2 diabetes 2022 Widely used for weight loss Zepbound Chronic weight management 2023 Minimal — used as approved What “off-label” means in practice:
Off-label prescribing is legal and extremely common in US medicine. A physician can legally prescribe Ozempic for weight loss in a non-diabetic patient — and millions do. However, insurance coverage for off-label use is significantly harder to obtain than for on-label indications. If your insurance covers GLP-1 medications for weight loss, Wegovy and Zepbound are the appropriate on-label choices.
Weight Loss Results — Clinical Trial Comparison
This is the most important comparison for most patients considering these medications.
Ozempic weight loss results (SUSTAIN trials)
Ozempic was studied for diabetes, not weight loss — so the weight loss data comes from secondary endpoints of diabetes trials. At the maximum diabetes dose of 2mg weekly:
- Average weight loss: 6–9% of body weight over 40 weeks
- For a 200lb person: approximately 12–18 lbs
- Note: patients in these trials were not specifically selected for weight loss
Wegovy weight loss results (STEP trials)
Wegovy was studied specifically for weight loss at its maximum dose of 2.4mg weekly:
- Average weight loss: 15% of body weight over 68 weeks (STEP 1 trial)
- For a 200lb person: approximately 30 lbs
- 35% of participants lost more than 20% of body weight
- Significantly better results than Ozempic at comparable timepoints
Mounjaro weight loss results (SURMOUNT trials)
Mounjaro was studied for diabetes but the SURMOUNT trials specifically examined weight loss outcomes:
- Average weight loss at 15mg dose: 21% of body weight over 72 weeks
- For a 200lb person: approximately 42 lbs
- 57% of participants lost more than 20% of body weight at highest dose
- Significantly outperforms both Ozempic and Wegovy on total weight loss
Head-to-head comparison table
Drug Average weight loss Best-case weight loss Trial duration Ozempic (2mg) 6–9% body weight ~15% 40 weeks Wegovy (2.4mg) 15% body weight 20%+ (35% of patients) 68 weeks Mounjaro (15mg) 21% body weight 20%+ (57% of patients) 72 weeks Important context: These are clinical trial averages. Individual results vary significantly based on starting weight, diet, exercise, metabolic factors, and adherence to treatment. Some patients lose far more than the average; others lose less. No drug guarantees a specific outcome.
Side Effects Comparison
All three drugs share similar GI side effect profiles because they all activate the GLP-1 receptor. The differences are in frequency and severity.
Common side effects — all three drugs
- Nausea — most common, most intense in weeks 1–4
- Vomiting — less common than nausea, more common at higher doses
- Constipation — ongoing throughout treatment
- Diarrhoea — less common than constipation
- Fatigue — particularly in the first 48 hours after injection
- Reduced appetite — intended effect but can become problematic
Side effect frequency comparison
Side effect Ozempic Wegovy Mounjaro Nausea 20% 44% 32% Vomiting 9% 24% 18% Constipation 11% 24% 11% Diarrhoea 9% 30% 17% Abdominal pain 7% 20% 9% Why Wegovy has more side effects than Ozempic: Wegovy is used at a higher maximum dose (2.4mg vs 2mg) — higher doses produce stronger GI effects. The dose-response relationship is direct and predictable.
Why Mounjaro’s profile differs: The dual GIP/GLP-1 mechanism appears to produce somewhat less severe GI effects than semaglutide at equivalent weight loss efficacy levels — though head-to-head data is limited.
Serious side effects — all three drugs
All three carry the same FDA black box warning for thyroid C-cell tumours based on rodent studies. All three carry risk of pancreatitis, gallbladder disease, and kidney problems from dehydration. These serious risks apply equally across all three drugs and are the reason all three require physician supervision.
Cost Comparison 2026
Cost is one of the most significant practical factors for US patients — and one of the most confusing, given the gap between retail price, insurance price, and telehealth compounded alternatives.
Retail price (without insurance)
Drug Monthly retail cost 2026 Ozempic ~$935 Wegovy ~$1,349 Mounjaro ~$1,023 Zepbound ~$1,059 With manufacturer savings cards (commercial insurance patients)
Drug Manufacturer card savings Eligible patients Ozempic As low as $25/mo Commercial insurance only Wegovy As low as $0/mo Commercial insurance only Mounjaro As low as $25/mo Commercial insurance only Zepbound As low as $25/mo Commercial insurance only Note: Manufacturer savings cards are not available to Medicare, Medicaid, or uninsured patients.
Compounded semaglutide (telehealth — uninsured patients)
For uninsured patients, compounded semaglutide through telehealth programmes provides by far the most affordable access:
Programme Monthly cost Drug Ro Body from $99 Compounded semaglutide SHED from $129 Compounded semaglutide MEDVi from $149 Compounded semaglutide No compounded tirzepatide programmes are available at scale as of August 2026 — Mounjaro and Zepbound have no affordable uninsured pathway comparable to compounded semaglutide.
This is a significant practical advantage of semaglutide over tirzepatide for uninsured patients: compounded semaglutide is legally available and affordable. Compounded tirzepatide is not yet widely available through regulated telehealth programmes.
Availability and Shortage Status
Drug shortages have significantly affected GLP-1 availability since 2022. Here is the current status as of August 2026:
Drug FDA shortage status Practical availability Ozempic On shortage list Variable by pharmacy and dose Wegovy Improving — partial shortage resolved Better than 2024–2025 Mounjaro Off shortage list (most doses) Generally available Zepbound Off shortage list Generally available Practical implications:
Ozempic shortage has driven patients toward compounded semaglutide alternatives — which remain legal as long as the shortage designation holds. Mounjaro and Zepbound being off the shortage list means compounding of tirzepatide is legally questionable — compounding pharmacies are no longer clearly permitted to produce it during non-shortage periods.
Insurance Coverage Comparison
Insurance coverage for GLP-1 medications varies enormously by plan and employer.
Drug Indication covered Typical insurance route Ozempic Type 2 diabetes coverage is standard Easy to get covered for T2D, difficult for obesity Wegovy Obesity coverage depends on plan Requires prior authorisation, BMI documentation Mounjaro Type 2 diabetes coverage is standard Similar to Ozempic for T2D Zepbound Obesity coverage depends on plan Requires prior authorisation The practical reality for obesity coverage:
As of 2026 approximately 50% of large employer health plans cover GLP-1 medications for obesity — up from 25% in 2023. If your plan covers GLP-1 for weight loss, Wegovy (semaglutide) and Zepbound (tirzepatide) are the appropriate on-label choices.
Medicare Part D covers Wegovy and Zepbound for obesity as of 2026 following legislation changes — a significant policy shift that has dramatically increased access for Medicare-eligible patients.
If your insurance does not cover GLP-1 for weight loss — compounded semaglutide through a telehealth programme remains the most affordable pathway for most uninsured or underinsured patients.
Who Should Choose Which Drug
This is a decision for you and your doctor — but here is the clinical logic that typically guides it:
Choose Ozempic if:
- You have type 2 diabetes and your doctor is prescribing for diabetes management
- Your insurance covers Ozempic for diabetes but not Wegovy for obesity
- You have responded well to Ozempic previously and want to stay on it
- Cost is a significant factor and you qualify for the $25/mo savings card
Choose Wegovy if:
- Your primary goal is weight loss without a diabetes diagnosis
- Your insurance covers GLP-1 for obesity — Wegovy is the on-label choice
- You want the highest-dose semaglutide option (2.4mg vs 2mg maximum)
- You are a Medicare patient — Wegovy now has Medicare obesity coverage
Choose Mounjaro if:
- You have type 2 diabetes and want maximum metabolic benefit
- Previous semaglutide use produced disappointing results
- Your insurance covers Mounjaro for diabetes
- You want the drug with the strongest weight loss clinical data
Choose Zepbound if:
- Your primary goal is weight loss (the on-label tirzepatide obesity option)
- You want maximum weight loss outcomes — Zepbound has the strongest data
- Your insurance covers GLP-1 for obesity
- You are willing to pay the higher retail cost for better results
Choose compounded semaglutide (telehealth) if:
- You are uninsured or your insurance does not cover GLP-1 for weight loss
- You need access within 1–2 weeks without an existing doctor relationship
- Budget is a primary concern — $99–$149/mo vs $935–$1,349/mo retail
Zepbound — Mounjaro’s Weight Loss Version
Many patients are confused about the Mounjaro vs Zepbound distinction — they are the same drug (tirzepatide) manufactured by Eli Lilly, packaged differently for different FDA indications.
Mounjaro: tirzepatide approved for type 2 diabetes. Covered by diabetes insurance plans.
Zepbound: tirzepatide approved for chronic weight management. Covered by obesity/weight loss insurance plans.
The active drug is chemically identical. The distinction matters for insurance — if you have diabetes your plan covers Mounjaro; if you need it for weight loss without diabetes your plan covers Zepbound.
Eli Lilly also offers Zepbound in vial form at a lower self-pay price ($399–$549/month) for patients without insurance coverage — a partial solution for the affordability gap, though still significantly more expensive than compounded semaglutide.
The Bottom Line
For maximum weight loss results, Mounjaro and Zepbound (tirzepatide) outperform both Ozempic and Wegovy based on current clinical evidence — producing an average of 21% body weight loss vs 15% for Wegovy and 6–9% for Ozempic.
For uninsured patients or those whose insurance does not cover GLP-1 for obesity, compounded semaglutide through a telehealth programme remains the most practical and affordable entry point — at $99–$149 per month compared to $935–$1,349 retail.
The right drug for you depends on your diagnosis, insurance coverage, weight loss goals, and tolerance for side effects. This is a conversation to have with your prescribing physician using the information in this guide.
Frequently Asked Questions
Is Mounjaro better than Ozempic for weight loss?
Based on clinical trial data, yes — significantly. Mounjaro (tirzepatide) produces an average of 21% body weight reduction compared to 6–9% for Ozempic (semaglutide at diabetes doses). The dual GLP-1/GIP mechanism of tirzepatide produces greater appetite suppression and metabolic benefit than GLP-1 activation alone. However, Mounjaro is not FDA-approved for weight loss in non-diabetic patients — Zepbound is the on-label tirzepatide weight loss drug.
Can I switch from Ozempic to Wegovy?
Yes. Both contain semaglutide. Switching from Ozempic to Wegovy is essentially a dose increase — Wegovy’s maximum dose (2.4mg) is higher than Ozempic’s maximum (2mg). Your physician will guide the transition. Most patients switch when their insurance changes coverage, when weight loss has plateaued on Ozempic, or when their indication changes from diabetes management to weight loss.
Is Wegovy the same as Ozempic?
They contain the same active ingredient — semaglutide — but are not identical. Wegovy is approved at a higher maximum dose (2.4mg vs 2mg) and is specifically approved for weight management rather than diabetes. The clinical outcomes differ partly because of the higher dose. Think of Wegovy as the higher-dose, weight-loss-specific version of the same drug class.
Why does my doctor prescribe Ozempic for weight loss if it is not approved for that?
Off-label prescribing is legal and extremely common in US medicine. Physicians can prescribe any approved drug for any condition they judge clinically appropriate. Ozempic’s weight loss effects are well-documented in clinical literature — doctors prescribe it off-label for obesity because the evidence supports efficacy. The main practical disadvantage is insurance coverage, which is harder to obtain for off-label use.
Which GLP-1 drug has the fewest side effects?
Based on clinical trial data, Ozempic at its standard diabetes doses has the lowest reported side effect rates — partly because it is used at lower doses than Wegovy. Mounjaro appears to have slightly lower GI side effect frequency than Wegovy at equivalent weight loss efficacy. All three drugs share the same mechanism-based GI side effects — the differences are of degree, not kind.
Can I take Ozempic and Mounjaro together?
No. Combining two GLP-1 receptor agonists or a GLP-1 with a dual GIP/GLP-1 agonist is not recommended and has not been studied for safety or efficacy in combination. The risk of severe GI side effects, hypoglycaemia, and other adverse events would be significant.
How long does it take to see results with each drug?
Most patients notice appetite suppression within the first 1–2 weeks on any of these medications. Meaningful weight loss (5%+ of body weight) typically takes 8–12 weeks. Maximum results based on clinical trials require 68–72 weeks of continuous treatment. Mounjaro shows faster early weight loss in some studies compared to semaglutide.
Sources: FDA prescribing information for Ozempic, Wegovy, Mounjaro, and Zepbound (2026), NEJM SUSTAIN 7 and STEP 1 trial data, SURMOUNT-1 trial data, CMS Medicare GLP-1 coverage update 2026, GoodRx pricing database August 2026.
Written and reviewed by the SemaglutideEdge editorial team. Last updated August 2, 2026.
